Drug Factories Ordered to Clean Up (China)
This article was originally published in PharmAsia News
Up until now, intense market rivalry has kept environmental concerns from becoming a priority for the Chinese pharmaceutical industry. But according to the country's environmental protection officials, that is all about to change. On Sept. 5 representatives for the State Environmental Protection Administration announced that over half of the country's pharmaceutical companies are in danger of being closed due to excessive pollution. Since July, China's environmental protection agency has been specifically targeting drug companies as part of an effort to reduce pollution in the country's rivers. Of the list of 6,066 environmentally destructive companies identified, 117 were drug makers. Now these companies must clean up their act or join the 649 businesses that have already been shut down. (Click here for more
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.